Form D · Biotechnology
Brenig Therapeutics, Inc.
Dover, DE · CIK 0002030788
Offering snapshot reported Jul 30, 2024 · SEC filing
- Reported sold
- $30M Offering amount: $65M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 16, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 30, 2024 | Initial | $30,000,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-520099
The Total Amount Sold includes the conversion of Convertible Promissory Notes with an aggregate principal amount plus accrued interest of approximately $7,837,105.
Source: Form D, filed Jul 30, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michele Cucullu | Director |
| Iain Dukes | Director, Executive |
| Keno Gutierrez | Director |
| Edward Mathers | Director |
| Nikolay Savchuk | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
8 The Green, Suite 8235
Dover, DE, 19901
Dover, DE, 19901